VitaNova Life Sciences Net Income Growth & History (VNOV)
VitaNova Life Sciences's net income was −$37,304 for fiscal 2026.
View full VitaNova Life Sciences company overviewVitaNova Life Sciences annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-04-30 | −$37,304 | −$888,050 | — |
| 2025 | 2025-04-30 | $850,746 | $709,881 | +503.94% |
| 2024 | 2024-04-30 | $140,865 | $165,092 | — |
| 2023 | 2023-04-30 | −$24,227 | −$163,909 | — |
| 2022 | 2022-04-30 | $139,682 | $191,776 | — |
| 2021 | 2021-04-30 | −$52,094 | $20,240 | — |
| 2020 | 2020-04-30 | −$72,334 | $33,833 | — |
| 2019 | 2019-04-30 | −$106,167 | −$104,572 | — |
| 2018 | 2018-04-30 | −$1,595 | — | — |
| 2017 | 2017-01-25 | −$7,175 | — | — |
VitaNova Life Sciences quarterly net income
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 | 2026-04-30 | $17,549 | −$782,783 | −97.81% |
| Q3 2026 | 2026-01-31 | −$44,362 | −$117,340 | — |
| Q2 2026 | 2025-10-31 | $35,810 | $3,163 | +9.69% |
| Q1 2026 | 2025-07-31 | −$46,301 | $8,910 | — |
| Q4 2025 | 2025-04-30 | $800,332 | $632,413 | +376.62% |
| Q3 2025 | 2025-01-31 | $72,978 | $67,030 | +1126.93% |
| Q2 2025 | 2024-10-31 | $32,647 | $41,402 | — |
| Q1 2025 | 2024-07-31 | −$55,211 | −$30,964 | — |
| Q4 2024 | 2024-04-30 | $167,919 | $172,304 | — |
| Q3 2024 | 2024-01-31 | $5,948 | $30,525 | — |
| Q2 2024 | 2023-10-31 | −$8,755 | −$11,356 | — |
| Q1 2024 | 2023-07-31 | −$24,247 | −$26,381 | — |
| Q4 2023 | 2023-04-30 | −$4,385 | $22,422 | — |
| Q3 2023 | 2023-01-31 | −$24,577 | −$33,494 | — |
| Q2 2023 | 2022-10-31 | $2,601 | −$12,408 | −82.67% |
| Q1 2023 | 2022-07-31 | $2,134 | −$140,429 | −98.50% |
| Q4 2022 | 2022-04-30 | −$26,807 | −$1,244 | — |
| Q3 2022 | 2022-01-31 | $8,917 | $11,816 | — |
| Q2 2022 | 2021-10-31 | $15,009 | $27,394 | — |
| Q1 2022 | 2021-07-31 | $142,563 | $153,810 | — |
| Q4 2021 | 2021-04-30 | −$25,563 | $774 | — |
| Q3 2021 | 2021-01-31 | −$2,899 | $3,695 | — |
| Q2 2021 | 2020-10-31 | −$12,385 | $7,134 | — |
| Q1 2021 | 2020-07-31 | −$11,247 | $8,637 | — |
| Q4 2020 | 2020-04-30 | −$26,337 | −$12,741 | — |
| Q3 2020 | 2020-01-31 | −$6,594 | $30,102 | — |
| Q2 2020 | 2019-10-31 | −$19,519 | $20,530 | — |
| Q1 2020 | 2019-07-31 | −$19,884 | −$4,058 | — |
| Q4 2019 | 2019-04-30 | −$13,596 | −$9,402 | — |
| Q3 2019 | 2019-01-31 | −$36,696 | −$23,946 | — |
| Q2 2019 | 2018-10-31 | −$40,049 | −$45,829 | — |
| Q1 2019 | 2018-07-31 | −$15,826 | −$25,395 | — |
| Q4 2018 | 2018-04-30 | −$4,194 | $2,981 | — |
| Q3 2018 · Jan 31 | 2018-01-31 | −$12,750 | — | — |
| Q3 2018 · Oct 31 | 2017-10-31 | $5,780 | — | — |
| Q2 2018 | 2017-07-31 | $9,569 | — | — |
| Q1 2018 | 2017-04-30 | −$7,175 | — | — |
VitaNova Life Sciences net income trends
Over the last five fiscal years, VitaNova Life Sciences's net income increased from −$52,094 to −$37,304, a change of $14,790. The latest reported quarter, Q4 2026, shows $17,549.
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review VitaNova Life Sciences source filings ↗